Even though the expression of MAGEA3 is generally confined to germline cells of the testis and placenta the same as other CTA, MAGEA3 may function as a potential immunotherapeutic target with its elevated expression in diverse malignant tumor cells including melanoma (19), lung cancer (20), and colorectal cancer (21). The gene discussed is MAGEA3; the disease is cancer.